Related content

125 I versus 103 Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial

By Wallner K.   Merrick G.   True L.   Sutlief S.   Cavanagh W.   Butler W.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 57, Iss. 5, 2003-12 ,pp. : 1297-1303

Elsevier

Access to resources Recommend Favorite

Marker seed migration in prostate localization

By Poggi M.M.   Gant D.A.   Sewchand W.   Warlick W.B.  

International Journal of Radiation Oncology*Biology*Physics, Vol. 56, Iss. 5, 2003-08 ,pp. : 1248-1251

Elsevier

Access to resources Recommend Favorite

Leuprolide Acetate: Once-Yearly Subcutaneous Implant in Advanced Prostate Cancer

By Croom K.F.   Perry C.M.  

American Journal of Cancer, Vol. 2, Iss. 1, 2003-01 ,pp. : 57-64

Adis International

Access to resources Recommend Favorite

Prostate cancer; the interface between pathology and basic scientific research

By Lalani E.-.N.   Stubbs A.   Stamp G.W.H.  

Seminars in Cancer Biology, Vol. 8, Iss. 1, 1997-02 ,pp. : 53-59

Academic Press

Access to resources Recommend Favorite

Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer - Kattan MW, Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY. Curr Opin Urol 2003; 13:111-116

By Carroll P.R.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 6, 2003-11 ,pp. : 484-485

Elsevier

Access to resources Recommend Favorite